TY - JOUR
T1 - The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia
AU - Lieve, Krystien V. V.
AU - Wilde, Arthur A.
AU - van der Werf, Christian
PY - 2016
Y1 - 2016
N2 - Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare but severe genetic cardiac arrhythmia disorder, with symptoms including syncope and sudden cardiac death due to polymorphic VT or ventricular fibrillation typically triggered by exercise or emotions in the absence of structural heart disease. The cornerstone of medical therapy for CPVT is β-blockers. However, recently flecainide has been added to the therapeutic arsenal for CPVT. In this review we summarise current data on the efficacy and role of flecainide in the treatment of CPVT
AB - Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare but severe genetic cardiac arrhythmia disorder, with symptoms including syncope and sudden cardiac death due to polymorphic VT or ventricular fibrillation typically triggered by exercise or emotions in the absence of structural heart disease. The cornerstone of medical therapy for CPVT is β-blockers. However, recently flecainide has been added to the therapeutic arsenal for CPVT. In this review we summarise current data on the efficacy and role of flecainide in the treatment of CPVT
U2 - https://doi.org/10.15420/aer.2016.3.3
DO - https://doi.org/10.15420/aer.2016.3.3
M3 - Article
C2 - 27403293
SN - 2050-3369
VL - 5
SP - 45
EP - 49
JO - Arrhythmia & electrophysiology review
JF - Arrhythmia & electrophysiology review
IS - 1
ER -